- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...
|
- Details
- During the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Anwar Padhani presents risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often). Biographies: Anwar Padhani, MBBS, FRCP, FRCR, Consultant, Radiologist & Professor, Cancer Imaging, Paul Strickla...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...
|
- Details
- Kim Chi presents an overview of how to read a genomics testing report during APCCC 2022. His presentation includes a discussion of prostate cancer-relevant genes, reading the FoundationOne CDx test, and more. Chi explains the importance of understanding the intricacies of the genomics report and its limitations given that tumor genomics is now a standard part of the workup for patients with advanc...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Maha Hussain presents the optimal treatment sequencing in metastatic castration-resistant prostate cancer (mCRPC). Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Can...
|
- Details
- Silke Gillessen facilitates the metastatic castration-resistant prostate cancer session discussion during the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 about treatment recommendations for metastatic castration-resistant prostate cancer. Topics covered include chemotherapy decisions regarding docetaxel and cabazitaxel, ADT, AR pathways, clinical trials versus real-world treatment,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Johann de Bono presents the role of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) patients focusing on the case for a selected, judicious use of PARP inhibitors in this setting. Biographies: Johann de Bono, MD, PhD, Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute o...
|
- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
